Screener
Trevi Therapeutics, Inc. TRVI EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss before income taxes | (13,212) | (10,351) |
| Income tax benefit | (20) | (11) |
| Net loss | $(13,192) | $(10,340) |
| Basic and diluted net loss per common share outstanding | $(0.09) | $(0.09) |
| Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted | 145,592,901 | 117,610,750 |
| Net loss | $(13,192) | $(10,340) |
| Other comprehensive (loss) income: | ||
| Net unrealized (losses) gains on available-for-sale marketable securities | (338) | 12 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Trevi Therapeutics, Inc.'s EPS (diluted)?
- Trevi Therapeutics, Inc. (TRVI) reported EPS (diluted) of -$0.09 in Q1 2026.
- How has Trevi Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Trevi Therapeutics, Inc.'s EPS (diluted) decreased by 0.0% year-over-year, from -$0.09 to -$0.09.
- What is the long-term trend for Trevi Therapeutics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s EPS (diluted) has grown at a -32.0% compound annual growth rate (CAGR), from -$1.50 to -$0.32.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Trevi Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude